Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CERo Therapeutics Holdings, Inc. filings document an emerging-growth biotechnology issuer with common stock and warrants and an operating focus on engineered T cell therapeutics. The company’s 8-K reports cover material definitive agreements, convertible promissory note financings, conversion mechanics, resale registration obligations, and exemptions used for private securities issuances.
Regulatory disclosures also include Regulation FD and other event reports tied to CER-1236 clinical presentations, notices concerning exchange listing status, and Form 12b-25 reporting on annual-report timing. These filings record CERO’s capital structure, public-company reporting status, governance and disclosure controls, and clinical-development communications.
CERo Therapeutics Holdings has filed a Prospectus Supplement No. 3 (424B3) updating their May 23, 2025 prospectus for 2,100,000 shares of common stock. The company's stock (NASDAQ: CERO) last traded at $9.56 per share, while its warrants (CEROW) traded at $0.0264.
The key development reported is that the FDA has granted Orphan Drug Designation to the company's lead drug candidate CER-1236 for treating acute myeloid leukemia, as announced on June 17, 2025.
As an emerging growth company, CERo Therapeutics trades on the Nasdaq Capital Market. The filing includes important risk disclosures for investors, and the company has not elected to use the extended transition period for complying with new financial accounting standards.
- Common stock par value: $0.0001 per share
- Warrants: Each exercisable for 1/2000th of a common share
- Principal office: South San Francisco, CA